Profile data is unavailable for this security.
About the company
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
- Revenue in USD (TTM)0.00
- Net income in USD-29.07m
- Incorporated2012
- Employees77.00
- LocationEnlivex Therapeutics Ltd14 Einstein St.NESS-ZIONA 7403618IsraelISR
- Phone+972 86623301
- Fax+972 86312981
- Websitehttps://www.enlivex.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acasti Pharma Inc | 0.00 | -38.77m | 28.48m | 32.00 | -- | 0.4403 | -- | -- | -5.06 | -5.06 | 0.00 | 6.88 | 0.00 | -- | -- | -- | -40.18 | -45.71 | -41.30 | -50.84 | -- | -- | -- | -69,798.47 | -- | -14.38 | 0.00 | -- | -- | -- | -332.11 | -- | -45.53 | -- |
| Singular Genomics Systems Inc | 2.91m | -94.82m | 29.57m | 255.00 | -- | 0.165 | -- | 10.16 | -1.30 | -1.30 | 0.04 | 2.42 | 0.0098 | 0.2182 | 3.94 | 11,415.69 | -31.96 | -- | -33.80 | -- | -19.17 | -- | -3,257.30 | -- | 9.77 | -- | 0.0474 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Aprea Therapeutics Inc | 583.24k | -14.29m | 29.59m | 7.00 | -- | 1.20 | -- | 50.74 | -4.00 | -4.00 | 0.1613 | 4.89 | 0.0221 | -- | -- | 83,320.00 | -54.11 | -68.66 | -63.19 | -77.19 | -- | -- | -2,449.55 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| Aptorum Group Ltd | 1.20m | -13.40m | 29.60m | 18.00 | -- | 1.28 | -- | 24.67 | -3.64 | -3.64 | 0.3234 | 4.22 | 0.0624 | 74.87 | 17.36 | 66,656.11 | -80.15 | -42.74 | -68.67 | -46.93 | 7.33 | -2.90 | -1,283.55 | -1,477.58 | 1.32 | -94.53 | 0.0066 | -- | -15.95 | -- | 60.88 | -- | -42.83 | -- |
| NKGen Biotech Inc | 0.00 | -82.95m | 29.69m | 63.00 | -- | -- | -- | -- | -5.24 | -5.24 | 0.00 | -2.68 | 0.00 | -- | -- | 0.00 | -86.93 | -- | -111.69 | -- | -- | -- | -- | -- | -- | -0.6077 | -- | -- | -- | -- | -1,923.83 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -10.23m | 30.42m | 8.00 | -- | -- | -- | -- | -1.01 | -1.01 | 0.00 | -0.2805 | 0.00 | -- | -- | 0.00 | -234.38 | -- | -317.07 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -3.47 | -- | -- | -- |
| Enlivex Therapeutics Ltd | 0.00 | -29.07m | 30.48m | 77.00 | -- | 1.00 | -- | -- | -1.56 | -1.56 | 0.00 | 1.62 | 0.00 | -- | -- | -- | -55.65 | -39.16 | -63.33 | -43.65 | -- | -- | -- | -- | -- | -42.92 | -- | -- | -- | -- | 6.41 | -- | -- | -- |
| Spruce Biosciences Inc | 10.09m | -47.92m | 30.52m | 29.00 | -- | 0.3977 | -- | 3.02 | -1.26 | -1.26 | 0.2622 | 1.86 | 0.1064 | -- | -- | 347,896.60 | -50.55 | -41.24 | -62.77 | -46.49 | -- | -- | -474.96 | -1,774.39 | -- | -107.65 | 0.0418 | -- | -- | -- | -3.77 | -- | -- | -- |
| DURECT Corp | 8.55m | -27.62m | 30.73m | 58.00 | -- | 2.03 | -- | 3.59 | -1.12 | -1.12 | 0.3257 | 0.4873 | 0.1624 | 0.7927 | 3.65 | 147,379.30 | -52.47 | -37.34 | -124.79 | -53.44 | 79.91 | 91.83 | -323.16 | -139.11 | 1.20 | -55.63 | 0.5299 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Dare Bioscience Inc | 2.81m | -30.16m | 31.38m | 23.00 | -- | -- | -- | 11.18 | -0.3444 | -0.3444 | 0.032 | -0.0505 | 0.0863 | -- | 2.12 | 122,082.20 | -92.65 | -109.51 | -463.87 | -246.26 | -- | -- | -1,074.17 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Earth Science Tech Inc | 5.98m | 330.94k | 31.49m | 8.00 | 104.17 | 14.59 | 59.49 | 5.26 | 0.001 | 0.001 | 0.0195 | 0.0069 | 3.16 | 11.41 | 106.07 | 747,970.00 | 17.50 | -224.84 | 42.70 | -- | 62.29 | 37.79 | 5.53 | -333.58 | 0.386 | -0.3899 | 0.1023 | -- | 243.77 | -36.31 | -111.95 | -- | -- | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.08m | 31.75m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
| Surrozen Inc | 0.00 | -43.04m | 32.31m | 42.00 | -- | 0.5493 | -- | -- | -21.35 | -21.35 | 0.00 | 18.39 | 0.00 | -- | -- | 0.00 | -63.52 | -- | -72.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -51.06m | 32.99m | 40.00 | -- | 2.55 | -- | -- | -1.32 | -1.32 | 0.00 | 0.4686 | 0.00 | -- | -- | 0.00 | -66.88 | -86.35 | -97.91 | -106.38 | -- | -- | -- | -11,853.94 | -- | -141.21 | 0.5798 | -- | -- | -- | -3.78 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Enlivex Therapeutics Ltd's reporting currency: US Dollar USD
1.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 31 Dec 2023 | 62.09k | 0.33% |
| KSM Mutual Funds Ltd.as of 31 Jan 2024 | 49.93k | 0.27% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 43.51k | 0.23% |
| Susquehanna Financial Group LLLPas of 31 Dec 2023 | 27.93k | 0.15% |
| Migdal Mutual Funds Ltd.as of 31 Jan 2024 | 23.95k | 0.13% |
| Simplex Trading LLCas of 31 Mar 2024 | 18.26k | 0.10% |
| Edmond de Rothschild (Suisse) SA (Investment Management)as of 31 Dec 2023 | 13.00k | 0.07% |
| Geode Capital Management LLCas of 31 Dec 2023 | 10.42k | 0.06% |
| Wells Fargo Clearing Services LLCas of 31 Dec 2023 | 9.99k | 0.05% |
| IBI Mutual Funds Management (1978) Ltd.as of 31 Jan 2024 | 7.50k | 0.04% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
